默沙东、GSK豪赌,恒瑞上桌,AZ、罗氏血战,千亿赛道开卷!

华尔街见闻
29 Jul

7月28日,恒瑞与GSK达成重磅合作,将共同开发至多12款创新药物。值得一提的是,协议包含一款潜在同类最优PDE3/4抑制剂(HRS-9821)的授权许可,该产品目前正处于慢性阻塞性肺疾病(COPD)治疗的临床开发阶段。短短20天,COPD赛道,突然之间变得刀光剑影。前有默沙东豪掷百亿并购,后有GSK霸气出手,并购、BD交易直接指向同一目标——COPD。这原本被视作研发“死亡谷”的领域,一夜之间...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10